Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitapivat for reduction of transfusion burden in sickle cell disease
PACTR202609539145927Phase 3Not yet recruiting
- Sponsor
- Agios Pharmaceuticals
- Start
- Feb 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in sickle cell disease (SCD) comparing Mitapivat with Placebo (2 arms). Primary endpoint: Transfusion free from Week 4 through Week 52. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
mitapivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202609539145927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202609539145927.